Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	7.57	13.38	53.96	54.4	94.9
Cash & Cash Equivalents	7.57	13.38	53.96	54.4	94.9
Cash Growth	-43.42%	-75.20%	-0.80%	-42.68%	-
Receivables	0	0.1	0.1	0.13	1.47
Other Current Assets	0.45	1.34	1.4	3.98	4.83
Total Current Assets	8.02	14.82	55.46	58.5	101.2
Property, Plant & Equipment	0	1.22	1.47	50.27	79.75
Long-Term Investments	5.35	0	0	3.84	4.99
Other Long-Term Assets	0	2.04	2.41	2.77	0.54
Total Long-Term Assets	5.35	3.26	3.87	56.88	85.28
Total Assets	13.37	18.08	59.33	115.38	186.48
Accounts Payable	1.2	2.97	1.83	1.44	3.31
Current Debt	0	0	0	6.8	3.42
Other Current Liabilities	0.89	4.66	9.26	8.72	11.52
Total Current Liabilities	2.09	7.63	11.09	16.95	18.25
Long-Term Debt	0	0	0	38.93	70.5
Total Long-Term Liabilities	0	0	0	38.93	70.5
Total Liabilities	2.09	7.63	11.09	55.89	88.75
Total Debt	0	0	0	45.74	73.92
Debt Growth	-	-	-	-38.13%	-
Retained Earnings	-264.42	-259.15	-215.08	-163.43	-85.63
Comprehensive Income	-0.01	-0.02	-0.02	-0.03	-0.02
Shareholders' Equity	11.29	10.45	48.25	59.49	97.73
Net Cash / Debt	7.57	13.38	53.96	8.66	20.98
Net Cash / Debt Growth	-43.42%	-75.20%	523.11%	-58.71%	-
Net Cash Per Share	3.24	6.16	-	-	-
Working Capital	5.94	7.19	44.37	41.55	82.95
Book Value Per Share	4.83	4.81	22.28	35.03	71.16

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).